Novocure
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
4/17/18: Final STELLAR data exceeded the results of the interim analysis for all efficacy endpoints. Novocure plans to submit a Humanitarian Device Exemption application to the FDA for approval
Novocure
Novocure’s Optune Now Available at More Than 600 Cancer Treatment Centers in the U.S.
Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM.
Novocure
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM). Optune is an FDA-approved Tumor Treating...
Novocure
Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
May 15, 2017 Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s Tumor Treating Fields (TTFields) delivery system as a Humanitarian Use Device (HUD) for the treatment of pleural mesothelioma. Novocure states the...
Novocure
Martin J. Madden Joins Novocure Board of Directors
The company said that Mr. Madden recently retired after a 30-year career in medical device innovation at Johnson & Johnson but recently served as Vice President, Research and Development DePuy-Synthes and Vice President Medical Device R&D Transformation Novocure...
